RT Journal Article
SR Electronic
T1 Disparity of secondary prevention among patients with rheumatic heart disease: A longitudinal study in Uganda
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.21.24304698
DO 10.1101/2024.03.21.24304698
A1 Xu, Xinpeng
A1 Chu, Emily
A1 Miao, Hui
A1 Du, Yuxian
A1 Hoskins, Ryan
A1 Opara, Chinonso C.
A1 Minja, Neema W.
A1 Pickersgill, Sarah
A1 Atala, Jenifer
A1 Beaton, Andrea Z.
A1 Kansiime, Rosemary
A1 Longenecker, Chris T.
A1 Nakitto, Miriam
A1 Ndagire, Emma
A1 Nalubwama, Hadija
A1 Okello, Emmy
A1 Sarnacki, Rachel
A1 Pulle, Jafesi
A1 Watkins, David A.
A1 Su, Yanfang
YR 2024
UL http://medrxiv.org/content/early/2024/03/24/2024.03.21.24304698.abstract
AB Background Rheumatic heart disease (RHD) is most prevalent in socially disadvantaged settings, placing a severe burden on patients and their households. The study aims to investigate the disparity of healthcare costs, including financial and time costs, among RHD patients in Uganda.Methods We enrolled 54 RHD households from the Uganda National RHD Registry between June 2019 and February 2021. The patients were interviewed in baseline and 12-month follow-up surveys. A random-effect model was applied to examine the disparity of RHD financial and time costs. Our primary outcomes are the total outpatient costs for RHD patients’ most recent visit, consisting of direct medical costs, direct non-medical costs, and time costs.Results Following the COVID-19 pandemic, the total financial cost of outpatient visits for RHD patients increased by 9 USD on average (P<0.01), with the change primarily driven by non-medical costs such as transportation and food (5.8 USD, P<0.05). Direct medical costs also increased significantly in the pandemic, with an average increase of 3.2 USD (P<0.1). Compared with their counterparts, non-medical costs were higher for patients with poor infrastructure, with less education, who were older, and who were male. Patients with employment experienced a higher time cost than those without (3.3 hours, P<0.01).Conclusions The COVID-19 pandemic significantly increased RHD outpatient costs, mainly caused by the increase in non-medical costs. Our study implies that improving infrastructure, investing in education, and providing employees with time to seek care have the potential to reduce non-medical barriers to RHD secondary prevention.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study was approved by the Makerere University School of Medical Research and Ethics Committee (REC RF 2018-082), the Uganda National Council for Science and Technology (SS 5081), and the University of Washington Department of Human Subjects Division (STUDY00002855). Participants provided written informed consent to participate in the study or, in the case of minors, the informed consent of their legal guardian or next of kin.Funding StatementThis study was supported by the American Heart Association (17SFRN33670611, 17SFRN33630027).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Makerere University School of Medical Research and Ethics Committee (REC RF 2018-082), the Uganda National Council for Science and Technology (SS 5081), and the University of Washington Department of Human Subjects Division (STUDY00002855). Participants provided written informed consent to participate in the study or, in the case of minors, the informed consent of their legal guardian or next of kin.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe raw data supporting the conclusions of this article is available upon request to the authors, without undue reservation. Supplementary file 1: Supplementary Tables. Table S1: Household Characteristics and Demographics. Table S2: Economic and Time Costs of Outpatient Visits. Table S3: Random Effects Model Estimation Results.